Investment Update U.K.-based Axol Bioscience, a specialist in induced pluripotent stem cell (iPSC) technologies, has secured $2.8 million (£2.1 million) in its latest funding round. This capital injection is earmarked to accelerate the firm’s growth in the North American market and enhance the production of human-relevant disease models for biomedical research.
Key Financial and Strategic Facts:
-
Funding Structure: The round was led by BroadOak Capital Partners, a U.S.-based life sciences specialist investor, with participation from founding backer The Roslin Foundation.
-
Expansion Objectives: The funds will support Axol’s commercial footprint in the U.S. while advancing the development of complex iPSC-derived models in neuroscience, ophthalmology, and cardiovascular diseases.
-
Infrastructure Upgrades: Beyond its U.S. focus, Axol plans to scale manufacturing capacity at its Edinburgh site in Scotland to meet rising global demand for in vitro testing models that offer alternatives to animal testing.
-
Strong Momentum: This investment follows a period of robust financial performance, with Axol reporting 45% revenue growth in 2025 and 36% in 2024.
-
Industry Outlook: BroadOak Capital Partners noted that Axol is well-positioned as global regulators increasingly adopt and encourage cell-based models for drug discovery and safety screening.